A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
A phase 2 trial of PM8002, Pemetrexed, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07680764 by Bristol-Myers Squibb, with 160 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-09-15. Interventions recorded: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre
Shares Pemetrexed, Bristol Myers Squibb, Paclitaxel / nab-paclitaxel, Cisplatin.
- TrialStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Shares PM8002, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialA Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.